Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Lung (Non-Small Cell)

Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology

Unique Data Set IDLungNo_EliLill_2008_148
DownloadableYes
SponsorEli Lilly & CompanyData ProviderEli LillyTotal Study Enrolled Patients598Comparator (Control) Arm Enrolled Patients297RandomizationYesClinicalTrial.gov IDNCT00686959ClinicalTrial.gov URLhttps://clinicaltrials.gov/ct2/results?term=JMIG&Search=Search
Study PhaseClinical Study Phase IIIBlinding MethodOpen Label StudyType(s) of dataOnly comparator arm dataIntervention TypeChemotherapy, RadiationData Set TypeADS

Clinical Trial Title

Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology

Trial Summary and Conditions

Study H3E-MC-JMIG (JMIG) is a multicenter, randomized, open-label, Phase 3 trial of patients with locally advanced, unresectable/inoperable, Stage III NSCLC other than predominantly squamous cell histology (nonsquamous) without malignant pleural/pericardial effusion. Approximately 600 patients will be randomized. Randomization will be at a 1:1 ratio between the experimental arm (Arm A; pemetrexed, cisplatin, and concurrent TRT for 3 cycles, followed by consolidation pemetrexed for 4 cycles), and the control arm (Arm B; etoposide, cisplatin, and concurrent TRT for 2 cycles, followed by consolidation with cytotoxic platinum-based doublet regimen of choice [excluding pemetrexed] for a maximum of 2 cycles). Concurrent chemoradiotherapy cycles are 21 days for Arm A, and 28 days for Arm B. Patients will be evenly randomized to treatment arms using an Interactive Voice Response System (IVRS) at a central location. The IVRS will assign patients to treatment arms according to a stratified method of randomization. In other words, there will be a separate and independent randomization within each of 16 strata or subgroups, defined by all 16 combinations of values of the following prognostic factors: ? Baseline ECOG performance status (0 versus 1) ? Gender (female versus male) ? Stage of disease (IIIA versus IIIB) ? PET scan (yes versus no).

Data Summary

Control arm data on demographics, safety, efficacy, treatment exposure, concomitant medications, medical history, and labs

Study Objectives

Primary Objective: To compare the overall survival (OS) of patients with locally advanced, Stage III NSCLC other than predominantly squamous cell histology (hereafter referred to as nonsquamous) treated with pemetrexed plus cisplatin and concurrent TRT, followed by consolidation chemotherapy with pemetrexed (Arm A) versus etoposide plus cisplatin and concurrent TRT, followed by consolidation with cytotoxic chemotherapy of choice (Arm B). The secondary objectives are: ?- to compare progression-free survival (PFS) between the 2 arms ? -to compare the first sites of disease failure in terms of relapse: within the radiation treatment field; intrathoracic out of field; distant disease; or some combination of these between the 2 arms ? -to compare the objective response rate (complete response [CR] + partial response [PR]) between the 2 arms ? -to compare 1-, 2-, and 3-year absolute survival rates between the 2 arms ? -to assess patient-reported outcomes (PROs) between the 2 arms using a swallowing diary -to estimate the incidence of adverse events from each treatment arm (acute and late toxicity)

Outcome Measures

Overall Survival, Progression-free survival (PFS), the first sites of disease failure, Objective response rate, swallowing diary, and incidence of adverse events.

Available Downloads:

To gain access to the data and analytic tools click here.

PROTOCOL: JMIG Protocol.pdf

CRF: H3E-MC-JMIG_eCRF_Redacted.pdf

DATA DICTIONARY: JMIG_ADS_Requirements_Final_Post_Prd1_Redacted.pdf

DATA (COMPARATOR ARM): JMIG_control_data.zip